MINGYANG TECHNOLOGY
837663
Shanghai Weihong Electronic Technology
300508
Shenzhen Intellifusion Technologies
688343
4
Est Tools Co., Ltd.
300488
5
Jiangyin Pivot Automotive Products
301181
US Stock MarketDetailed Quotes
TWST Twist Bioscience
- 41.200
- -0.110-0.27%
Close Feb 24 16:00 ET
- 41.200
- 0.0000.00%
Pre 04:30 ET
2.46BMarket Cap-12.19P/E (TTM)
42.330High40.600Low1.06MVolume41.670Open41.310Pre Close43.86MTurnover1.80%Turnover RatioLossP/E (Static)59.65MShares60.90052wk High5.39P/B2.41BFloat Cap27.41052wk Low--Dividend TTM58.58MShs Float214.070Historical High--Div YieldTTM4.19%Amplitude11.460Historical Low41.490Avg Price1Lot Size
Twist Bioscience Stock Forum
Sign in to post a comment
The attention of AI Medteck stocks are rapidly increasing.
Pelosi's new holdings have doubled $Tempus AI (TEM.US)$ value in just a few weeks, and $Firefly Neuroscience (AIFF.US)$'s inclusion in NVIDIA's Connect program has also caused its stock price to soar.
In addition, DeepSeek's rapid rise has boosted the AI application sector, particularly in medicine/healthcare. Cathie Wood believes medical AI is undervalued, with untapped pot...
Pelosi's new holdings have doubled $Tempus AI (TEM.US)$ value in just a few weeks, and $Firefly Neuroscience (AIFF.US)$'s inclusion in NVIDIA's Connect program has also caused its stock price to soar.
In addition, DeepSeek's rapid rise has boosted the AI application sector, particularly in medicine/healthcare. Cathie Wood believes medical AI is undervalued, with untapped pot...
112
13
277
US Congress member Nancy Pelosi and Ark Invest's Cathie Wood both bet big on an AI stock recently.
The stock in question is $Tempus AI (TEM.US)$, a company that uses data and artificial intelligence (AI) to create precision medicine services. ARK Invest, a prominent advocate for innovative technologies, first showed interest on December 6, when it purchased shares in this healthcare technology firm. Since that initial investment, Tempus AI h...
The stock in question is $Tempus AI (TEM.US)$, a company that uses data and artificial intelligence (AI) to create precision medicine services. ARK Invest, a prominent advocate for innovative technologies, first showed interest on December 6, when it purchased shares in this healthcare technology firm. Since that initial investment, Tempus AI h...
45
7
154
Cathie Wood and Ark Invest's trade activity from today 9/10
$ARK Innovation ETF (ARKK.US)$ :
Bought $Advanced Micro Devices (AMD.US)$ $DraftKings (DKNG.US)$ $Tempus AI (TEM.US)$
Sold $Unity Software (U.US)$ $Palantir (PLTR.US)$ $Twist Bioscience (TWST.US)$ $Veracyte (VCYT.US)$
By the way..
Palantir $PLTR is on fire this year
It's up over 109% YTD, just got included in the S&P500, and today Bank of America raised their price target to $50 a share
D. E. Shaw owns almost $500 million worth of shares, more than any...
$ARK Innovation ETF (ARKK.US)$ :
Bought $Advanced Micro Devices (AMD.US)$ $DraftKings (DKNG.US)$ $Tempus AI (TEM.US)$
Sold $Unity Software (U.US)$ $Palantir (PLTR.US)$ $Twist Bioscience (TWST.US)$ $Veracyte (VCYT.US)$
By the way..
Palantir $PLTR is on fire this year
It's up over 109% YTD, just got included in the S&P500, and today Bank of America raised their price target to $50 a share
D. E. Shaw owns almost $500 million worth of shares, more than any...
2
How does the biotech ecosystem support advancements in personalized medicine & genomics? ![]()
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...
9
2
Twist Bioscience's P/S ratio remains lower due to sub-par revenue outlook, indicating investor expectation of limited future growth. Shareholder pessimism around future revenue growth contributes to this lower ratio.
Twist Bioscience's optimistic cash runway and manageable burn rate are noteworthy despite the need for vigilance as the firm grows. Its market cap also points to easy fundraising potential.
Despite Twist Bioscience's unprofitability, rapid revenue growth indicates positive prospects. However, persistent share price decline hints at capital raising issues. Investors should assess the firm's balance sheet, market conditions and specific risks.
$Twist Bioscience (TWST.US)$ Twist Bioscience Announced An Antibody Discovery, Option And License Agreement With Bayer Of Up To $188M. Bayer Will Have The Option To License Antibodies Discovered Under The Collaboration
No comment yet
Trending Stocks
Discussing
Widespread uptick! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets.
Moomoo News Global
Feb 24 22:30
Can Chinese Stocks Stretch 6-Week Rally? Wall Street Stays Bullish on Top Picks
Buy n Die Together❤ :
73610841 : Adrian Nathaniel carter, I can’t tag him and we’re Facebook friends, does anyone know why?
Seth Beaty : Though you know if you bet against Cathie Wood, you’ll probably make money.
Rob banks : is there an ETF for this ai medical sector?
Chak : is it goid time yo
get into TEM ?
View more comments...